AstraZeneca Stock News

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results equate to an objective response rate (CRs and PRs) of 63% Data from an earlier cutoff date in February are included in an abstract published today ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and add...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cance...

AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer lived without their disease coming back or getting worse. The data, released Friday, come from the company's phase III POTOMAC trial and mark a potential breakthrough for patients with high-risk non...

Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator.  Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research.

Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.

AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,6...

AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R...